Interventional Oncology Market Report Suite | United States | 2016-2022 | MedSuite
The interventional oncology (IO) device market encompasses many different types of methodical approaches to the treatment of cancer. As the cancer epidemic continues to flourish in the U.S., so too do a vast variety of treatment options all designed to increase patient survival, comfort and affordability.
- Year: 2016
- Scope: 2012-2022
- Region: United States
- Published Date: 2/1/2016
- Pages: 230
- Type: MedSuite
The transcatheter embolization particle segment is expected to lead the other segments in growth, driven by the strong adoption of radioactive particles, which command significantly higher ASPs. Similarly, the tumor ablation device segment is expected to exhibit market growth due to an ongoing shift towards newer and more expensive modalities.
Although declining in value, the external and internal radiation therapy device segments will be experiencing rising procedure volumes. Market decline in the external radiation therapy segment will be driven by fluctuations in the number of new system installations on an annual basis. Meanwhile, the market decline in the internal radiation therapy segment will be primarily driven by falling prices.
This report also includes an analysis of other factors and trends that have positively and negatively impacted the market.
The interventional oncology (IO) device market encompasses many different types of methodical approaches to the treatment of cancer. As the cancer epidemic continues to flourish in the U.S., so too do a vast variety of treatment options all designed to increase patient survival, comfort and affordability. Despite multiple challenges such as declining ASPs and expensive capital investment, growth is expected for the overall market as the patient demographics in the U.S. maintain a steady demand for cancer treatments. The transcatheter embolization particle segment will be the fastest growing in the market, and will be continually driven by novel and emerging technologies.
Competition amongst the different modalities will continue to limit the market. Many of the product segments discussed and analyzed as part of the interventional oncology device market can be considered direct substitutes or alternatives to another. As such, growth in procedural volumes for one area often leads to cannibalization of another.
Interventional Oncology Market Report Data Types Included
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Forecasts Until 2022, and Historical Data to 2012
- Market Drivers & Limiters for Each Device Segment
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
- Disease Overviews and Demographic Information
- Company Profiles, Product Portfolios and SWOT for Top Competitors
- Related Press Releases from Top Competitors
Interventional Oncology Companies Analyzed
Varian led the overall interventional oncology device market in 2015. This was primarily due to the company’s commanding position in the external radiation therapy device segment, which accounted for a large majority of the overall market. In addition to the external radiation therapy device segment, the company was also a leading player in the internal radiation therapy device market.
Elekta held the second-leading position in the overall interventional oncology device market. This was primarily due to the company’s large share of the external radiation therapy device segment, which accounted for a large majority of the overall market. In addition, the company also held the commanding position in the internal radiation therapy device segment. Similar to Varian, Elekta has a strong global presence in the overall radiation therapy market space.
Companies researched in this report includes Sirtex, BTG, Merit Medical Systems, AngioDynamics, C.R. Bard, Boston Scientific, Best Medical, HealthTronics, Cook Medical, Perseon, MedWaves, Accuray, Pfizer, Vascular Solutions and various others.
Our reports follow an in-depth 9-step methodology which focuses on the following research systems:
- Original primary research that consists of the most up-to-date market data
- Strong foundation of quantitative and qualitative research
- Focused on the needs and strategic challenges of the industry participants
Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.
Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.
Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.
Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.
Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.
Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.
Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.
Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.
Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.